Clarus Lifesciences III, L.P. 4
4 · Entasis Therapeutics Holdings Inc. · Filed Oct 2, 2018
Insider Transaction Report
Form 4
Clarus Lifesciences III, L.P.
10% Owner
Transactions
- Conversion
Common Stock
2018-09-28+361,829→ 361,829 total(indirect: See Footnote) - Conversion
Common Stock
2018-09-28+323,341→ 685,170 total(indirect: See Footnote) - Conversion
Common Stock
2018-09-28+412,583→ 1,170,010 total(indirect: See Footnote) - Purchase
Common Stock
2018-09-28$15.00/sh+453,395$6,800,925→ 1,623,405 total(indirect: See Footnote) - Conversion
Series B Convertible Preferred Stock
2018-09-28−7,500,000→ 0 total(indirect: See Footnote)→ Common Stock (361,829 underlying) - Conversion
Series B-1 Tranche A Convertible Preferred Stock
2018-09-28−6,702,213→ 0 total(indirect: See Footnote)→ Common Stock (323,341 underlying) - Conversion
Series B-1 Tranche B Convertible Preferred Stock
2018-09-28−8,552,024→ 0 total(indirect: See Footnote)→ Common Stock (412,583 underlying)
Footnotes (3)
- [F1]Each share of Series B Preferred Stock, Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the "Preferred Stock") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.
- [F2]The reportable securities are held directly by Clarus Lifesciences III, L.P. ("Clarus III"). Clarus Ventures III GP, L.P. ("Clarus III GP") is the sole general partner of Clarus III. Clarus Ventures III, LLC ("Clarus III GP LLC") is the sole general partner of Clarus III GP. Nicholas Galakatos, Dennis Henner, Robert Liptak, Scott Requadt, Nicholas Simon, and Kurt Wheeler are the managing directors of Clarus III GP LLC (the "Managing Members"). Each of Clarus III GP, Clarus III GP LLC and the Managing Members may be deemed to beneficially own the securities held by Clarus III. Each of Clarus III GP, Clarus III GP LLC and the Managing Members disclaims beneficial ownership of these securities, except to the extent of their respective pecuniary interests therein.
- [F3]This number includes an aggregate of 72,257 shares of Common Stock received upon the conversion of the Issuer's Preferred Stock as payment of the accrued dividends through September 27, 2018. No dividends will accrue after September 27, 2018.